Carl Zeiss Meditec to acquire DORC International
Click Here to Manage Email Alerts
Key takeaways:
- Carl Zeiss Meditec AG will acquire Dutch Ophthalmic Research Center in 2024.
- The transaction is valued at approximately 985 million.
Carl Zeiss Meditec AG has entered into an agreement to acquire all shares of Dutch Ophthalmic Research Center, according to a press release.
The acquisition will cost approximately 985 million euros (approximately US$1.073 billion) and is expected to be complete in the first half of 2024.
DORC’s assets include the Eva Nexus platform, which previously received FDA 510(k) clearance for subretinal injection and is designed to allow for the performance of a variety of vitreoretinal, cataract and combined procedures on a single system.
The acquisition will build Zeiss’ ophthalmic portfolio of treatments and workflow solutions for retinal disorders, cataracts, glaucoma and refractive errors, the release said.
“Meeting our customers’ growing surgical needs to improve patients’ lives is the cornerstone of this acquisition,” Euan S. Thomson, PhD, head of the ophthalmology strategic business unit and head of the digital business unit for Zeiss Medical Technology, said in the press release.
Read more about
Click Here to Manage Email Alerts